Loading...
Cart
0

Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous and Subcutaneous): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

LI_172586
Pages: 220
Nov 2018 | 7207 Views
 
Author(s) : Onkar Sumant and Kavita Joshi
Tables: 133
Charts: 87
 

Immunoglobulin Market Overview:

The global immunoglobulin market was valued at $9,972.9 million in 2017 and is expected to reach $16,694.7 million by 2025, CAGR of  6.6% from 2018 to 2025. Immunoglobulin, also referred to as antibody is a protein produced by plasma cells and other lymphocytes. It is complex entity that exerts its immunomodulatory effect on different components of the immune system. It is obtained from blood through the process of fractionation and is purified for therapeutic and non-therapeutic applications. Different classes of immunoglobulin, IgG, IgA, IgD, IgE, and IgM, are used for the treatment of various immunological and neurological diseases. These immunoglobulins are administered through intravenous and subcutaneous modes of delivery.

The major factors that fuel the market growth during the forecast period include increase in geriatric population & number of hemophilic patients, improved immunoglobulin production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield). Furthermore, surge in prevalence diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia & others are expected to boost the market growth. However, stringent government regulations toward immunoglobulin products and high risk of side effects owing to the use of immunoglobulin are expected to hamper the growth of the market.

Get more information on this report : Request Sample Pages

Application segment review

Based on application, the immunoglobulin market is divided into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. The hypogammaglobulinemia segment was the highest contributor to the market in 2017 and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the significant increase in prevalence of hypogammaglobulinemia disorder across the globe over the years. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its incidence rate is ~2 per 100,000 population yearly, globally.

Get more information on this report : Request Sample Pages

Mode of delivery segment review

Based on mode of delivery, the immunoglobulin market is classified into intravenous and subcutaneous. The intravenous segment accounted for the highest revenue in 2017 and is expected to maintain its dominance throughout the forecast period. High bioavailability of immunoglobulins and rapid absorption rate offered by intravenous mode of delivery are the factors that supplement the growth of the intravenous mode of delivery immunoglobulin market.

Get more information on this report : Request Sample Pages

Region segment review

Based on region, the immunoglobulin market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the largest contributor toward the global market, followed by Asia-Pacific. These regions collectively occupy almost 75% of the global market revenue. Presence of the largest plasma production facilities and high adoption rate in the developed countries majorly boost the market growth. However, LAMEA is projected to register the highest growth rate during the forecast period.

The report provides extensive competitive analysis and profiles of key market players that includes Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., Shire (Baxalta), and Bayer Healthcare.

Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

Key Benefits for Immunoglobulin Market:

  • The study provides an in-depth analysis of the global immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.

  • A comprehensive analysis of the factors that drive and restrict the market growth is provided.

  • A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.

  • An extensive analysis of the key segments of the industry helps understand the trends in the global immunoglobulin treatment market.

  • Key players and their strategies are provided to understand the competitive outlook of the industry.

Immunoglobulin Key Market Segments:

By Application

  • Hypogammaglobulinemia

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • Immunodeficiency Disease

  • Myasthenia Gravis

  • Multifocal Motor Neuropathy

  • Idiopathic Thrombocytopenic Purpura (ITP)

  • Inflammatory Myopathies

  • Specific Antibody Deficiency

  • Guillain‐Barré Syndrome

  • Others

By Product

  • IgG

  • IgA

  • IgM

  • IgE

  • IgD

By Mode of Delivery

  • Intravenous

    • 5% Concentration

    • 10% Concentration

    • Others

  • Subcutaneous

    • 16.5% Concentration

    • 20% Concentration

    • Others

By Region

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • France

    • Germany

    • Italy

    • Austria

    • Russia

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • LAMEA

    • Saudi Arabia

    • Argentina

    • Brazil

    • Turkey

    • Rest of LAMEA

 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools & models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Overview of immunoglobulin

3.2.1.    Patented products
3.2.2.    Epidemiology and economic burden of chronic conditions

3.3.    Key findings

3.3.1.    Top investment pockets
3.3.2.    Top Winning Strategies

3.4.    Porter’s five forces analysis
3.5.    Value chain analysis

3.5.1.    Primary activities
3.5.2.    Support activities

3.6.    Market share analysis, 2017
3.7.    Product scenario in Immunoglobulin market
3.8.    Government regulations and reimbursements

3.8.1.    U.S.
3.8.2.    Europe
3.8.3.    France
3.8.4.    Germany
3.8.5.    Italy
3.8.6.    China
3.8.7.    Japan
3.8.8.    India

3.9.    Indications for immunoglobulin

3.9.1.    U.S. FDA indications
3.9.2.    EMA

3.10.    Component analysis of immunoglobulin G (IgG)

3.10.1.    IgG1
3.10.2.    IgG2
3.10.3.    IgG3
3.10.4.    IgG4

3.11.    Market dynamics

3.11.1.    Drivers

3.11.1.1.    Rise in prevalence of immunodeficiency diseases
3.11.1.2.    Increase in adoption of immunoglobulin
3.11.1.3.    Growth in incidence of bleeding disorders
3.11.1.4.    Surge in geriatric population

3.11.2.    Restraints

3.11.2.1.    Stringent government regulations
3.11.2.2.    High cost of therapy

3.11.3.    Opportunities

3.11.3.1.    Opportunities in emerging economies
3.11.3.2.    Development of cost-effective therapeutics through large-scale production

CHAPTER 4:    IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Hypogammaglobulinemia

4.2.1.    Market size and forecast

4.3.    Chronic Inflammatory demyelinating polyneuropathy (CIDP)

4.3.1.    Market size and forecast

4.4.    Primary immunodeficiency diseases

4.4.1.    Market size and forecast

4.5.    Myasthenia Gravis

4.5.1.    Market size and forecast

4.6.    Multifocal motor neuropathy

4.6.1.    Market size and forecast

4.7.    Idiopathic thrombocytopenic purpura (ITP)

4.7.1.    Market size and forecast

4.8.    Inflammatory myopathies

4.8.1.    Market size and forecast

4.9.    Specific antibody deficiency

4.9.1.    Market size and forecast

4.10.    Guillain-barre syndrome

4.10.1.    Market size and forecast

4.11.    Others

4.11.1.    Market size and forecast

CHAPTER 5:    IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1.    Overview

5.1.1.    IGG
5.1.2.    Key market trends
5.1.3.    Clinical interpretations
5.1.4.    IGA
5.1.5.    Key Market Trends
5.1.6.    Clinical interpretation
5.1.7.    IGM
5.1.8.    Key Market Trends
5.1.9.    Clinical interpretation
5.1.10.    IGE
5.1.11.    Key Market Trend
5.1.12.    Clinical interpretation
5.1.13.    IGD
5.1.14.    Key Market Trends
5.1.15.    Clinical interpretation

CHAPTER 6:    IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Intravenous mode of delivery

6.2.1.    Key Market Trends
6.2.2.    Market size and forecast

6.2.2.1.    5% concentration

6.2.2.1.1.    Market size and forecast

6.2.2.2.    10% Concentration

6.2.2.2.1.    Market size and forecast

6.2.2.3.    Other Concentrations

6.2.2.3.1.    Market size and forecast

6.3.    Subcutaneous mode of delivery

6.3.1.    Key Market Trends
6.3.2.    Market size and forecast

6.3.2.1.    16.5% Concentration

6.3.2.1.1.    Market size and forecast

6.3.2.2.    20% Concentration

6.3.2.2.1.    Market size and forecast

6.3.2.3.    Other Concentration

6.3.2.3.1.    Market size and forecast

CHAPTER 7:    IMMUNOGLOBULIN MARKET, BY REGION

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    North America

7.2.1.    Key trends and opportunities
7.2.2.    North America market size & forecast, by application
7.2.3.    North America market size & forecast, by mode of delivery
7.2.4.    North America market size & forecast, by country

7.2.4.1.    U.S. market size & forecast
7.2.4.2.    Canada market size & forecast
7.2.4.3.    Mexico market size & forecast

7.3.    Europe

7.3.1.    Key trends and opportunities
7.3.2.    Europe market size & forecast, by application
7.3.3.    Europe market size & forecast, by mode of delivery
7.3.4.    Europe market size & forecast for immunoglobulin market, by country

7.3.4.1.    Germany market size & forecast
7.3.4.2.    France market size & forecast
7.3.4.3.    UK market size & forecast
7.3.4.4.    Italy market size & forecast
7.3.4.5.    Austria market size & forecast
7.3.4.6.    Russia market size & forecast
7.3.4.7.    Rest of Europe market size & forecast

7.4.    Asia-Pacific

7.4.1.    Key trends and opportunities
7.4.2.    Asia-Pacific market size & forecast, by country
7.4.3.    Asia-Pacific market size & forecast, by application
7.4.4.    Asia-Pacific market size & forecast, by mode of delivery

7.4.4.1.    Australia market size & forecast
7.4.4.2.    China market size & forecast
7.4.4.3.    India market size & forecast
7.4.4.4.    Japan market size & forecast
7.4.4.5.    Rest of Asia-Pacific market size & forecast

7.5.    LAMEA

7.5.1.    Key trends and opportunities
7.5.2.    LAMEA market size & forecast, by country
7.5.3.    LAMEA market size & forecast, by application
7.5.4.    LAMEA market size & forecast, by mode of delivery

7.5.4.1.    Brazil market size & forecast
7.5.4.2.    Saudi Arabia market size & forecast
7.5.4.3.    Argentina market size & forecast
7.5.4.4.    Rest of LAMEA market size & forecast

CHAPTER 8:    COMPANY PROFILES

8.1.    BAXTER INTERNATIONAL INC.

8.1.1.    Company overview
8.1.2.    Company snapshot
8.1.3.    Operating business segments
8.1.4.    Product portfolio
8.1.5.    Business performance
8.1.6.    Key strategic moves and developments

8.2.    BAYER AG

8.2.1.    Company overview
8.2.2.    Company snapshot
8.2.3.    Operating business segments
8.2.4.    Product portfolio
8.2.5.    Business performance
8.2.6.    Key strategic moves and developments

8.3.    BIOTEST AG

8.3.1.    Company overview
8.3.2.    Company snapshot
8.3.3.    Operating business segments
8.3.4.    Product portfolio
8.3.5.    Business performance

8.4.    CHINA BIOLOGIC PRODUCTS, INC.

8.4.1.    Company overview
8.4.2.    Company snapshot
8.4.3.    Operating business segments
8.4.4.    Product portfolio
8.4.5.    Business performance

8.5.    CSL LIMITED

8.5.1.    Company overview
8.5.2.    Company snapshot
8.5.3.    Operating business segments
8.5.4.    Product portfolio
8.5.5.    Business performance
8.5.6.    Key strategic moves and developments

8.6.    GRIFOLS S.A.

8.6.1.    Company overview
8.6.2.    Company snapshot
8.6.3.    Operating business segments
8.6.4.    Product portfolio
8.6.5.    Business performance
8.6.6.    Key strategic moves and developments

8.7.    KEDRION BIOPHARMA INC.

8.7.1.    Company overview
8.7.2.    Company snapshot
8.7.3.    Operating business segments
8.7.4.    Product portfolio
8.7.5.    Business performance

8.8.    LFB SA (LFB BIOTECHNOLOGIES SAS)

8.8.1.    Company overview
8.8.2.    Company snapshot
8.8.3.    Operating business segments
8.8.4.    Product portfolio
8.8.5.    Business performance

8.9.    OCTAPHARMA AG

8.9.1.    Company overview
8.9.2.    Company snapshot
8.9.3.    Operating business segments
8.9.4.    Product portfolio
8.9.5.    Business performance

8.10.    SHIRE PLC.(BAXALTA)

8.10.1.    Company overview
8.10.2.    Company snapshot
8.10.3.    Operating business segments
8.10.4.    Product portfolio
8.10.5.    Business performance
8.10.6.    Key strategic moves and developments

LIST OF TABLES

TABLE 01.    COMMERCIALIZED IMMUNOGLOBULIN PRODUCTS
TABLE 02.    BASELINE IMMUNOGLOBULIN YEARLY COSTS (2009)
TABLE 03.    U.S. FDA INDICATIONS FOR IMMUNOGLOBULIN
TABLE 04.    EMA-APPROVED INDICATIONS FOR IMMUNOGLOBULIN
TABLE 05.    IGG SUBCLASS
TABLE 06.    FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 07.    DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY
TABLE 08.    GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 09.    GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAM)
TABLE 10.    COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 11.    GLOBAL IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 2017–2025 ($MILLION)
TABLE 12.    GLOBAL IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 13.    GLOBAL IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 2017–2025 ($MILLION)
TABLE 14.    GLOBAL IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 15.    GLOBAL IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION, 2017–2025 ($MILLION)
TABLE 16.    GLOBAL IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION, 2017–2025 (KILOGRAMS)
TABLE 17.    GLOBAL IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 2017–2025 ($MILLION)
TABLE 18.    GLOBAL IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 2017–2025 (KILOGRAMS)
TABLE 19.    GLOBAL IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2017–2025 ($MILLION)
TABLE 20.    GLOBAL IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 21.    GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION,  2017–2025 ($MILLION)
TABLE 22.    GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION,  2017–2025 (KILOGRAMS)
TABLE 23.    GLOBAL IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 2017–2025 ($MILLION)
TABLE 24.    GLOBAL IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 25.    GLOBAL IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 2017–2025 ($MILLION)
TABLE 26.    GLOBAL IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 2017–2025 (KILOGRAMS)
TABLE 27.    GLOBAL IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME, BY REGION, 2017–2025 ($MILLION)
TABLE 28.    GLOBAL IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME), BY REGION, 2017–2025 (KILOGRAMS)
TABLE 29.    GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 2017–2025 ($MILLION)
TABLE 30.    GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 31.    GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 ($MILLION)
TABLE 32.    GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 (KILOGRAMS)
TABLE 33.    IMMUNOGLOBULIN MARKET, FOR INTRAVENOUS, BY REGION, 2017–2025 ($MILLION)
TABLE 34.    IMMUNOGLOBULIN MARKET, FOR INTRAVENOUS, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 35.    IMMUNOGLOBULIN MARKET, FOR SUBCUTANEOUS MODE OF DELIVERY, BY REGION, 2017–2025 ($MILLION)
TABLE 36.    IMMUNOGLOBULIN MARKET, FOR SUBCUTANEOUS MODE OF DELIVERY, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 37.    GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 38.    GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 2017–2025 (KILOGRAMS)
TABLE 39.    NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 40.    NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAMS)
TABLE 41.    NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 ($MILLION)
TABLE 42.    NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 KILOGRAMS)
TABLE 43.    NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 44.    NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 (KILOGRAMS)
TABLE 45.    EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 46.    EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAMS)
TABLE 47.    EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 ($MILLION)
TABLE 48.    EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 (KILOGRAMS)
TABLE 49.    EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 50.    EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 (KILOGRAMS)
TABLE 51.    ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 52.    ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 (KILOGRAMS)
TABLE 53.    ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 54.    ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAMS)
TABLE 55.    ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 ($MILLION)
TABLE 56.    ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 (KILOGRAMS)
TABLE 57.    LAMEA IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 58.    LAMEA IMMUNOGLOBULIN MARKET, BY COUNTRY, 2017–2025 (KILOGRAMS)
TABLE 59.    LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 60.    LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2017–2025 (KILOGRAMS)
TABLE 61.    LAMEA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 ($ MILLION)
TABLE 62.    LAMEA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2017–2025 (KILOGRAMS)
TABLE 63.    BAXTER: COMPANY SNAPSHOT
TABLE 64.    BAXTER: OPERATING SEGMENTS
TABLE 65.    BAXTER: PRODUCT PORTFOLIO
TABLE 66.    BAYER: COMPANY SNAPSHOT
TABLE 67.    BAYER: OPERATING SEGMENTS
TABLE 68.    BAXTER: PRODUCT PORTFOLIO
TABLE 69.    BIOTEST: COMPANY SNAPSHOT
TABLE 70.    BIOTEST: OPERATING SEGMENTS
TABLE 71.    BIOTEST: OPERATING SEGMENT
TABLE 72.    CHINA BIOLOGIC COMPANY SNAPSHOT
TABLE 73.    CHINA BIOLOGIC PRODUCT PORTFOLIO
TABLE 74.    CSL: COMPANY SNAPSHOT
TABLE 75.    CSL: PRODUCT SEGMENTS
TABLE 76.    CSL: PRODUCT PORTFOLIO
TABLE 77.    GRIFOLS: COMPANY SNAPSHOT
TABLE 78.    GRIFOLS: OPERATING SEGMENTS
TABLE 79.    GRIFOLS: PRODUCT PORTFOLIO
TABLE 80.    KEDRION: COMPANY SNAPSHOT
TABLE 81.    KEDRION: PRODUCT PORTFOLIO
TABLE 82.    LFB: COMPANY SNAPSHOT
TABLE 83.    LFB: PRODUCT SEGMENTS
TABLE 84.    LFB: PRODUCT PORTFOLIO
TABLE 85.    OCTAPHARMA: COMPANY SNAPSHOT
TABLE 86.    OCTAPHARMA: PRODUCT SEGMENTS
TABLE 87.    OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 88.    SHIRE: COMPANY SNAPSHOT
TABLE 89.    SHIRE: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    IMMUNOGLOBULIN MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS
FIGURE 03.    TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 04.    TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 05.    TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 06.    LOW BARGAINING POWER OF SUPPLIERS
FIGURE 07.    LOW BARGAINING POWER OF BUYERS
FIGURE 08.    LOW THREAT OF SUBSTITUTION
FIGURE 09.    LOW THREAT OF NEW ENTRANTS
FIGURE 10.    MODERTAE COMPETITIVE RIVALRY
FIGURE 11.    VALUE CHAIN ANALYSIS
FIGURE 12.    MARKET SHARE ANALYSIS, 2017
FIGURE 13.    GLOBAL IMMUNOGLOBULIN MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 14.    IMMUNOGLOBULIN MARKET, FOR 5% CONCENTRATION, 2017–2025 ($MILLION)
FIGURE 15.    IMMUNOGLOBULIN MARKET, FOR 5% CONCENTRATION, 2017–2025 (KILOGRAMS)
FIGURE 16.    IMMUNOGLOBULIN MARKET, FOR 10% CONCENTRATION, 2017–2025 ($MILLION)
FIGURE 17.    IMMUNOGLOBULIN MARKET, FOR 10% CONCENTRATION, 2017–2025 (KILOGRAMS)
FIGURE 18.    IMMUNOGLOBULIN MARKET, FOR 10% CONCENTRATION, 2017–2025 ($MILLION)
FIGURE 19.    IMMUNOGLOBULIN MARKET, FOR 10% CONCENTRATION, 2017–2025 ($MILLION)
FIGURE 20.    IMMUNOGLOBULIN MARKET, FOR 16.5% CONCENTRATION, 2017–2025 ($MILLION)
FIGURE 21.    IMMUNOGLOBULIN MARKET, FOR 16.5% CONCENTRATION, 2017–2025 (KILOGRAMS)
FIGURE 22.    IMMUNOGLOBULIN MARKET, FOR 16.5% CONCENTRATION, 2017–2025 ($MILLION)
FIGURE 23.    IMMUNOGLOBULIN MARKET, FOR 16.5% CONCENTRATION, 2017–2025 (KILOGRAMS)
FIGURE 24.    IMMUNOGLOBULIN MARKET, FOR OTHER CONCENTRATION, 2017–2025 ($MILLION)
FIGURE 25.    IMMUNOGLOBULIN MARKET, FOR OTHER CONCENTRATION, 2017–2025 (KILOGRAMS
FIGURE 26.    U.S. IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 27.    U.S. IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 28.    CANADA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 29.    U.S. IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 30.    MEXICO IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 31.    MEXICO IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 32.    GERMANY IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 33.    GERMANY IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 34.    FRANCE IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 35.    FRANCE IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 36.    UK IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 37.    UK IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 38.    ITALY IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 39.    ITALY IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 40.    AUSTRIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 41.    AUSTRIA IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 42.    RUSSIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 43.    RUSSIA IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 44.    REST OF EUROPE IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 45.    REST OF EUROPE IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 46.    AUSTRALIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 47.    AUSTRALIA IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 48.    CHINA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 49.    CHINA IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 50.    INDIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 51.    INDIA IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 52.    JAPAN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 53.    JAPAN IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 54.    REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 55.    REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 56.    BRAZIL IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 57.    BRAZIL IMMUNOGLOBULIN MARKET, 2017-2025 (KILOGRAMS)
FIGURE 58.    SAUDI ARABIA IMMUNOGLOBULIN MARKET, 2017–2025 ($MILLION)
FIGURE 59.    SAUDI ARABIA IMMUNOGLOBULIN MARKET, 2017–2025 (KILOGRAMS)
FIGURE 60.    ARGENTINA IMMUNOGLOBULIN MARKET, 2017–2025 ($MILLION)
FIGURE 61.    ARGENTINA IMMUNOGLOBULIN MARKET, 2017–2025 (KILOGRAMS)
FIGURE 62.    REST OF LAMEA IMMUNOGLOBULIN MARKET, 2017–2025 ($MILLION)
FIGURE 63.    REST OF LAMEA IMMUNOGLOBULIN MARKET, 2017–2025 (KILOGRAMS)
FIGURE 64.    BAXTER: NET SALES, 2015–2017 ($MILLION)
FIGURE 65.    BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 66.    BAYER: NET SALES, 2015–2017 ($MILLION)
FIGURE 67.    BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 68.    BAYER: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 69.    BIOTEST: NET SALES, 2015–2017 ($MILLION)
FIGURE 70.    BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 71.    BIOTEST: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 72.    CHINA BIOLOGIC NET SALES, 2015–2017 ($MILLION)
FIGURE 73.    CSL: NET SALES, 2015–2017 ($MILLION)
FIGURE 74.    CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 75.    CSL: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 76.    GRIFOLS: NET SALES, 2015–2017 ($MILLION)
FIGURE 77.    GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 78.    GRIFOLS: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 79.    KEDRION: NET SALES, 2015–2017 ($MILLION)
FIGURE 80.    KEDRION: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 81.    LFB: NET SALES, 2014–2016 ($MILLION)
FIGURE 82.    LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
FIGURE 83.    LFB: REVENUE SHARE BY REGION, 2016 (%)
FIGURE 84.    OCTAPHARMA: NET SALES, 2015–2017 ($MILLION)
FIGURE 85.    SHIRE: NET SALES, 2015–2017 ($MILLION)
FIGURE 86.    SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 87.    SHIRE: REVENUE SHARE BY REGION, 2017 (%)

 
 

The immunoglobulin products gained significant attention in the recent years due to their efficacy in the treatment of immune diseases. Immunoglobulin is considered to be the most effective treatment for hypogammaglobulinemia, CIDP, and immunodeficiency diseases, which are the largest immunoglobulin consuming indications in the global immunoglobulin market, owing to the large patient population and unavailability of effective alternative treatments.

Presence of limited number of plasma donors hampers the market growth. To resolve this, immunoglobulin producers have appealed to the local government for favorable pricing policy in selective regions of the market and they have successfully gained support from government authorities. Therefore, the average price of immunoglobulin is projected to remain relatively stable during the forecast period.

Moreover, the substantial development in technology involved in plasma production and purification is expected to significantly increase the immunoglobulin production. In addition, the key players have decided to strengthen their research activities for the development of therapies for rare diseases through immunoglobulin products, which are anticipated to provide growth opportunities in the immunoglobulin market.

The administration of immunoglobulin is the highest in North America, owing to the increase in adoption of immunoglobulin products, high awareness regarding the benefits of using immunoglobulin therapies among the healthcare providers, and increase in disposable income among patients. Although the use of immunoglobulin in LAMEA is low, the adoption rate is expected to increase due to rise in disposable income, surge in healthcare expenditure, and government initiative to enhance the healthcare departments. These factors contribute toward the market growth.

 

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Download Sample

Request Customization

 

Download Sample

OR

Purchase Full Report of
Immunoglobulin Market

  • Online Only
  • $3456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample

Buy Full Version
"Immunoglobulin Market"
Purchase Enquiry